HCW Biologics Inc (HCWB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.87 (-4.10%), Market cap $0.01B, 52-week low–high $0.27 ~ $8.37.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the
Financial statements, price targets, institutional (13F) holdings and related news for HCW Biologics Inc are updated in real time on BlackAll Trade.
HCW Biologics Inc trades at $1.87 (-4.10%). Real-time quotes and charts are available on BlackAll Trade.
HCW Biologics Inc has a market cap of about $0.01B.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its